Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | October 22, 2014 |
| Target | Motus Therapeutics |
| Sector | Life Science |
| Buyer(s) | Allergan |
| Sellers(s) | Rhythm Pharmaceuticals |
| Deal Type | Divestiture |
| Deal Value | 40M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1956 |
| Sector | Life Science |
| Employees | 31,200 |
| Revenue | 15.8B USD (2018) |
Allergan is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.
| Deal Context for Buyer | # |
|---|---|
| Overall | 18 of 38 |
| Sector: Life Science | 11 of 23 |
| Type: Divestiture | 5 of 7 |
| Country: United States | 11 of 27 |
| Year: 2014 | 5 of 5 |
| Size (of disclosed) | 25 of 25 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-10-06 |
Durata Therapeutics
Chicago, Illinois, United States Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. |
Buy | $675M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-01-26 |
Auden Mckenzie Holdings
Ruislip, United Kingdom Auden Mckenzie Holdings Ltd is a privately owned, dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the U.K. |
Buy | £306M |
| Category | Company |
|---|---|
| Founded | 2008 |
| Sector | Medical Products |
Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in gastrointestinal diseases and obesity, including obesity caused by genetic deficiencies in the MC4 pathway.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2014 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-27 |
Motus Therapeutics
Boston, United States Motus Therapeutics, Inc. is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. |
Buy | - |
